دورية أكاديمية
أعرض في EDS

Pediatric autoimmune myelofibrosis: Experience from a large pediatric tertiary care center.

التفاصيل البيبلوغرافية
العنوان: Pediatric autoimmune myelofibrosis: Experience from a large pediatric tertiary care center.
المؤلفون: Kim TO; Texas Children's Cancer and Hematology Center, Houston, Texas, USA.; Departments of Pediatrics and Pathology & Immunology, Baylor College of Medicine, Houston, Texas, USA., Curry CV; Departments of Pediatrics and Pathology & Immunology, Baylor College of Medicine, Houston, Texas, USA.; Texas Children's Hospital, Department of Pathology, Houston, Texas, USA., Wiszniewska J; Departments of Pathology and Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA., Elghetany MT; Departments of Pediatrics and Pathology & Immunology, Baylor College of Medicine, Houston, Texas, USA.; Texas Children's Hospital, Department of Pathology, Houston, Texas, USA., Satter LRF; Departments of Pediatrics and Pathology & Immunology, Baylor College of Medicine, Houston, Texas, USA.; Immunology Allergy and Retrovirology and William T. Shearer Texas Children's Hospital Center for Human Immunobiology, Houston, Texas, USA., Grimes AB; Texas Children's Cancer and Hematology Center, Houston, Texas, USA.; Departments of Pediatrics and Pathology & Immunology, Baylor College of Medicine, Houston, Texas, USA., Despotovic JM; Texas Children's Cancer and Hematology Center, Houston, Texas, USA.; Departments of Pediatrics and Pathology & Immunology, Baylor College of Medicine, Houston, Texas, USA.
المصدر: Pediatric blood & cancer [Pediatr Blood Cancer] 2023 Apr; Vol. 70 (4), pp. e30144. Date of Electronic Publication: 2023 Jan 20.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: John Wiley Country of Publication: United States NLM ID: 101186624 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1545-5017 (Electronic) Linking ISSN: 15455009 NLM ISO Abbreviation: Pediatr Blood Cancer Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hoboken, N.J. : John Wiley, c 2004-
مواضيع طبية MeSH: Primary Myelofibrosis*/pathology , Autoimmune Diseases*/diagnosis , Lupus Erythematosus, Systemic* , Leukopenia*, Adult ; Adolescent ; Humans ; Child ; Tertiary Care Centers
مستخلص: Autoimmune myelofibrosis (AIMF) is a rare disorder characterized by cytopenias and autoimmunity, with characteristic bone marrow findings that include lymphocytic infiltration and fibrosis. AIMF is described predominantly in adult populations who have systemic lupus erythematosis (SLE), with scant pediatric cases described mainly in older adolescents with SLE. Here, we described the largest single-center pediatric experience of pediatric autoimmune myelofibrosis (PAIMF) series, demonstrating both similarities and distinctions from the adult experience. Patients overall respond well to steroid therapy, but these patients were significantly younger, infrequently carried a diagnosis of SLE, and causative genetic lesions were identified in many cases.
(© 2023 Wiley Periodicals LLC.)
References: Piatek CI, Vergara-Lluri ME, Pullarkat V, et al. Autoimmune myelofibrosis: clinical features, course, and outcome. Acta Haematol. 2017;138(3):129-137.
Marcellino B, El Jamal SM, Mascarenhas JO. Distinguishing autoimmune myelofibrosis from primary myelofibrosis. Clin Adv Hematol Oncol. 2018;16(9):619-626.
Kvasnicka HM, Beham-Schmid C, Bob R, et al. Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study. Histopathology. 2016;68(6):905-915.
DeLario MR, Sheehan AM, Ataya R, et al. Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis-an entity different from adults. Am J Hematol. 2012;87(5):461-464.
Mishra P, Halder R, Aggarwal M, et al. Pediatric myelofibrosis: WHO 2024 update on myeloproliferative neoplasms calling. Pediatr Blood Cancer. 2020;67(5):e28232.
Agarwal BR, Bhalla K, Dalvi R, Currimbhoy ZE, Mehta KP. Myelofibrosis secondary to SLE and its reversal on steroid therapy. Indian Pediatr. 1995;32(11):1207-1210.
Chalayer E, Ffrench M, Cathebras P. Bone marrow fibrosis as a feature of systemic lupus erythematosus: a case report and literature review. SpringerPlus. 2014;3:349.
Cummer E, Donaldson B, Marlowe E, Rosenthal NS, Dixon N, Harry O. Autoimmune myelofibrosis as a presenting feature of childhood-onset systemic lupus erythematosus: a case report with review of pediatric literature. J Clin Rheumatol. 2021:27(8S):S378-S381. https://doi.org/10.1097/rhu.0000000000001533.
Daly HM, Scott GL. Myelofibrosis as a cause of pancytopenia in systemic lupus erythematosus. J Clin Pathol. 1983;36(11):1219-1222.
el Mouzan MI, Ahmad MA, al Fadel Saleh M, al Sohaibani MO, al Gindan YM. Myelofibrosis and pancytopenia in systemic lupus erythematosus. Acta Haematol. 1988;80(4):219-221.
Kiss E, Gal I, Simkovics E, et al. Myelofibrosis in systemic lupus erythematosus. Leuk Lymphoma. 2000;39(5-6):661-665.
Lee AC, Fong CM. Autoimmune myelofibrosis as the first manifestation of human immunodeficiency virus infection in an infant. Ann Hematol. 2012;91(5):809-810.
Nakao T, Fukushima T, Shimizu T, et al. Transient myelofibrosis with autoimmune pancytopenia: a case report. Eur J Pediatr. 2009;168(8):1003-1006.
Paquette RL, Meshkinpour A, Rosen PJ. Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. Medicine (Baltimore). 1994;73(3):145-152.
Pilorget H, Bangui A, Adam M, Leverger G. Myelofibrosis regressing under corticotherapy and intravenous immunoglobulins in an infant. Arch Pediatr. 1996;3(1):40-43.
Ramakrishna R, Kyle PW, Day PJ, Manoharan A. Evans' syndrome, myelofibrosis and systemic lupus erythematosus: role of procollagens in myelofibrosis. Pathology (Phila). 1995;27(3):255-259.
Hashmi SK, Bergstrom K, Bertuch AA, et al. PSTPIP1-associated myeloid-related proteinemia inflammatory syndrome: a rare cause of childhood neutropenia associated with systemic inflammation and hyperzincemia. Pediatr Blood Cancer. 2019;66(1):e27439.
Forbes LR, Vogel TP, Cooper MA, et al. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018;142(5):1665-1669.
تواريخ الأحداث: Date Created: 20230120 Date Completed: 20230224 Latest Revision: 20230226
رمز التحديث: 20230226
DOI: 10.1002/pbc.30144
PMID: 36661251
قاعدة البيانات: MEDLINE
الوصف
تدمد:1545-5017
DOI:10.1002/pbc.30144